IVF Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Gynecol Obstet Invest. 2013;76(2):113-8. doi: 10.1159/000351570. Epub 2013 Jul 30.
BACKGROUND/AIMS: To evaluate the feasibility of a long protocol of controlled ovarian stimulation prior to in vitro fertilization (IVF) and embryo transfer with a gonadotropin-releasing hormone (GnRH) antagonist used for pituitary and ovarian suppression.
Thirty patients undergoing IVF/intracytoplasmic sperm injection were randomized into two groups. The control group (n = 16) received a standard flexible GnRH antagonist protocol. Ovarian stimulation consisted of 225 IU/day of recombinant follicle-stimulating hormone for 5 days, followed by 225 IU/day of human menopausal gonadotropin until human chorionic gonadotropin (hCG) administration. The study group (n = 14) received 0.25 mg of GnRH antagonist daily for 7 days, thereafter, upon confirmation of pituitary and ovarian suppression, ovarian stimulation was commenced with the same protocol as used in the control group. Hormone and follicle dynamics, as well as laboratory characteristics and cycle outcome, were compared for both groups.
Both groups were comparable in baseline characteristics. Pituitary and ovarian suppression were effectively achieved in 12/14 patients in the study group. The duration of ovarian stimulation and gonadotropin consumption were similar in both groups, as was also the number and size of follicles on hCG day.
The results of our study confirm the feasibility of a long GnRH antagonist protocol. This regimen could become another option to optimize GnRH antagonist protocols, and should thus be further explored.
背景/目的:评估使用促性腺激素释放激素(GnRH)拮抗剂进行垂体和卵巢抑制的体外受精(IVF)和胚胎移植前长方案控制性卵巢刺激的可行性。
30 名接受 IVF/胞浆内精子注射的患者被随机分为两组。对照组(n = 16)接受标准的灵活 GnRH 拮抗剂方案。卵巢刺激包括 5 天每天 225IU 的重组卵泡刺激素,然后每天 225IU 的人绝经促性腺激素,直至人绒毛膜促性腺激素(hCG)给药。研究组(n = 14)每天接受 0.25mg GnRH 拮抗剂 7 天,此后,在确认垂体和卵巢抑制后,开始使用与对照组相同的方案进行卵巢刺激。比较两组的激素和卵泡动力学、实验室特征和周期结局。
两组在基线特征方面具有可比性。研究组中 12/14 名患者有效实现了垂体和卵巢抑制。两组的卵巢刺激持续时间和促性腺激素消耗相似,hCG 日的卵泡数量和大小也相似。
我们的研究结果证实了长 GnRH 拮抗剂方案的可行性。该方案可能成为优化 GnRH 拮抗剂方案的另一种选择,因此应进一步探索。